FDA Approves ZITHROMAX — Pfizer Laboratories Div Pfizer Inc
**Pfizer’s board utilizes AZITHROMYCIN DIHYDRATE in oral form to reintroduce the heavy-hitter branded antibiotic ZITHROMAX, reinstating a potent revenue driver that may reduce reliance on generic erosion and drive volume growth amid the ongoing lung infection season.**
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed